Chongqing Pharscin Pharmaceutical Co Ltd (002907.SZ) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · China · ISIN CNE100003308

Price
13.54 CNY
Market cap
5.65 bn CNY
P/E (2025)
86.87
P/S (2025)
6.84
Dividend yield
0.55 %
Net margin
7.87 %
Return on equity (ROE)
3.85 %
Return on assets (ROA)
3.21 %

Chongqing Pharscin Pharmaceutical Co Ltd financials

Fiscal year20242025
Revenue774.82 m CNY827.14 m CNY
Gross profit441.91 m CNY474.67 m CNY
Operating income93.80 m CNY69.62 m CNY
EBIT92.95 m CNY77.60 m CNY
Net income76.73 m CNY65.09 m CNY
Diluted EPS – continuing operations0.18 CNY0.16 CNY

Full history since 2013, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Chongqing Pharscin Pharmaceutical Co Ltd

Chongqing Pharscin Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of drugs in China and internationally. It offers generic drugs, traditional Chinese medicines, and food for special medical purposes in various forms, including tablets, granules, capsules, soft capsules, powders, powder injections, lyophilized powder injections, small-volume injections, chemical raw materials, and traditional Chinese medicine extracts. The company is also involved in the provision of CDMO and CMO services; pharmaceutical technology development services and consulting; wholesale and retail activities; and scientific research and technical services. Its products are used in digestive diseases, central nervous system disorders, and otolaryngology therapeutic areas. The company was incorporated in 1996 and is headquartered in Chongqing, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.